The Food and Drug Administration has approved a new heart failure drug from Novartis that has been shown to reduce death and hospitalizations from the condition.Excitement has been growing for the drug, known as Entresto, since the results of a large clinical trial were announced nearly a year ago showing a 20 percent reduction in the risk of death from cardiovascular causes or hospitalization for worsening heart failure.In a somewhat unusual move for a pharmaceutical company, Novartis has predicted that Entresto could eventually achieve more than $5 billion in annual sales globally, making it one of the world’s best-selling medications.“This is one of those once-in-a-decade kind of breakthroughs, to get a drug that extends life so substantially,” David Epstein, the head of Novartis’ pharmaceutical division, said in an interview.
[“source=food.ndtv”]
